Zhang, P., Wang, Y., Li, J., Shen, L., Lu, M. (2025). Updated results from a multicenter, single-arm phase II study of surufatinib plus sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e16342